Novo Nordisk's Split Analyst Verdicts, a Weekly Insulin Approval and a Buyback Ledger Converge on 4 November

Two research houses have reached the same cautious destination by different routes on Novo Nordisk. Oddo BHF lifted its price target on the Danish drugmaker while keeping its rating at "Neutral," a combination that upgrades the perceived upside without endorsing the stock outright. HSBC, according to media reports, reaffirmed its hold recommendation. The pair thus diverge on direction but not on restraint — and neither has issued a clean buy signal, even after a run of product and capital-return news.

That distinction matters. A higher target is a recalibration of valuation headroom, not a change of stance, and Oddo BHF's sizable increase should not be read as an unqualified vote of confidence.

What the buyback actually says

Alongside the analyst moves, Novo Nordisk's repurchase programme offers a concrete capital measure rather than a verdict on the business. The company disclosed on 19 October that it had bought back 39,074,179 B shares through 16 October, spending DKK 10,875,024,304 at an average price of DKK 278.32 per share. Those figures describe completed purchases, not the full scope of the plan, which authorises up to DKK 15 billion over twelve months from 4 February. The distinction between the envelope and what has been executed is the one that counts for valuation.

A regulatory win, and a data caveat

Friday brought a genuine regulatory decision: the US Food and Drug Administration approved Awiqli as an add-on to diet and exercise for children aged ten and older with type 2 diabetes. Per the FDA, it is the first once-weekly basal insulin for this patient group — cutting basal insulin injections from seven a week to one.

CagriSema sits at a different stage entirely. The compound remains in clinical testing, and results published on Tuesday came from post-hoc analyses of the phase 3 REDEFINE 1 trial. Among 2,309 women with overweight or obesity who adhered to treatment, average weight loss reached 25.0%, against 3.0% on placebo, over a treatment course running to week 68. Reuters noted on Tuesday that the full study, with more than 3,400 adults, showed 22.7% weight loss — short of Novo Nordisk's own 25% goal. The subgroup finding, however striking, cannot be equated with the result for the entire trial population.

The yardstick that outranks all of it

None of these items — an approved label, a mid-stage asset's subgroup analysis, or executed buybacks — substitutes for evidence on how the underlying business is performing. That evidence arrives on 4 November, when Novo Nordisk reports third-quarter 2026 results. The print will give investors an independent measure against which the medical progress and the capital returned to shareholders can be weighed.